Related Experiment Video
Updated: Jul 9, 2026

Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
Giulia Chinetti-Gbaguidi1, Bart Staels
1Institut Pasteur de Lille, 1, Rue Calmette BP245, Lille, F-59019, France. giulia.chinetti@pasteur-lille.fr
Abstract:
The metabolic syndrome is defined as a clustering of cardiovascular risk factors with insulin resistance, including dyslipidemia, coagulation disturbances and hypertension. Activators of the peroxisome proliferator-activated receptors (PPARs) modulate several of the metabolic risk factors predisposing to atherosclerosis. Fibrates are hypolipidemic drugs acting through activation of PPARalpha, whereas glitazones are insulin sensitizers activating PPARgamma. In addition, these drugs exert pleiotropic anti-inflammatory actions. In this review, we will focus on the effects of fibrates and glitazones on biomarker modulation and their usefulness in the treatment of cardiovascular disease.
Related Concept Videos
Measurement of Bioavailability: Pharmacodynamic Methods
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Therapeutic Drug Monitoring: Drug Analysis Methods
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Therapeutic Drug Monitoring: Affecting Factors